Are you Dr. Zojwalla?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 63 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
161 Fort Washington Ave
New York, NY 10032Phone+1 212-305-5056
Summary
- Dr. Naseem Zojwalla, MD is an oncologist in New York, New York. She is currently licensed to practice medicine in New York.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2002 - 2005
Temple University HospitalResidency, Internal Medicine, 1998 - 2001
Lewis Katz School of Medicine at Temple UniversityClass of 1998
Certifications & Licensure
NY State Medical License Active through 2013
Clinical Trials
- A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies Start of enrollment: 2006 Jan 01
- Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma Start of enrollment: 2007 Sep 01
Publications & Presentations
PubMed
- 147 citationsInhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.Toni K. Choueiri, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan
Nature Medicine. 2021-04-22 - 223 citationsPhase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Car...Kevin D. Courtney, Jeffrey R. Infante, Elaine T. Lam, Robert A. Figlin, Brian I. Rini
Journal of Clinical Oncology. 2017-12-19 - 31 citationsBelzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome.Junne Kamihara, Kayla V. Hamilton, Jessica A. Pollard, Catherine Clinton, Jill A. Madden
The New England Journal of Medicine. 2021-11-25
Press Mentions
Olema Oncology Appoints Naseem Zojwalla, M.D., as Chief Medical OfficerJanuary 31st, 2022- Olema Oncology Appoints Naseem Zojwalla, M.D., as Chief Medical OfficerJanuary 31st, 2022
- Olema Oncology Appoints Naseem Zojwalla, M.D., as Chief Medical OfficerJanuary 31st, 2022
- Join now to see all
